Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Anoro Ellipta (umeclidinium/vilanterol) and Symbicort (budesonide/formoterol) are both inhalers used to manage chronic obstructive pulmonary disease (COPD), but they have some key differences. Anoro Ellipta combines a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA), while Symbicort combines a corticosteroid and a LABA. Anoro Ellipta is taken once daily, whereas Symbicort is taken twice daily. Symbicort is also approved for treating asthma, unlike Anoro Ellipta. Anoro Ellipta does not have a generic version, making it potentially more expensive, while Symbicort is available in generic forms. Additionally, Anoro Ellipta does not require mouth rinsing after use, but Symbicort does to prevent thrush. Both medications are not suitable for sudden breathing problems and should be used as long-term maintenance treatments.
Symbicort (budesonide / formoterol) is a combination inhaler used to treat asthma and chronic obstructive pulmonary disease (COPD). It contains two medications: budesonide, a steroid, and formoterol, a long-acting beta-agonist (LABA). Both medications work together to reduce inflammation in the lungs and open up your airways. The typical dose is two puffs by mouth twice a day, usually about 12 hours apart. Common side effects include common cold symptoms, headache, and sore throat.